# Processa Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2014

- Company: [Processa Pharmaceuticals, Inc.](/companies/pcsa.md) (CIK 1533743)
- Form: 10-Q
- Filed: 2014-11-13
- Accepted by EDGAR: Nov 13, 2014, 16:56 ET
- Period: 2014-09-30
- Accession: 0001393905-14-000606
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1533743/000139390514000606/huwx_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1533743/000139390514000606/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-07-01 to 2014-09-30 | $52.6k | us-gaap:Revenues |
| Revenue | 9 months, 2014-01-01 to 2014-09-30 | $185.8k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2014-07-01 to 2014-09-30 | $25.3k | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2014-01-01 to 2014-09-30 | $104.6k | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2014-07-01 to 2014-09-30 | $27.3k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2014-01-01 to 2014-09-30 | $81.2k | us-gaap:GrossProfit |
| Research and development | 3 months, 2014-07-01 to 2014-09-30 | $11.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2014-01-01 to 2014-09-30 | $180.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2014-07-01 to 2014-09-30 | $677.4k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2014-01-01 to 2014-09-30 | $2.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2014-07-01 to 2014-09-30 | −$130.1k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2014-01-01 to 2014-09-30 | −$303.2k | us-gaap:InterestExpense |
| Income tax | 3 months, 2014-07-01 to 2014-09-30 | −$25 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2014-01-01 to 2014-09-30 | −$75 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2014-07-01 to 2014-09-30 | −$792.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2014-01-01 to 2014-09-30 | −$3.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-07-01 to 2014-09-30 | −$0.10 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2014-01-01 to 2014-09-30 | −$0.37 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2014-01-01 to 2014-09-30 | −$2.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2014-01-01 to 2014-09-30 | $25.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2014-09-30 | $55.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-09-30 | $400.6k | us-gaap:AssetsCurrent |
| Total assets | at 2014-09-30 | $2.7m | us-gaap:Assets |
| Current liabilities | at 2014-09-30 | $809.5k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-09-30 | $2.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2014-09-30 | −$116.8k | us-gaap:StockholdersEquity |
| Shares outstanding | at 2014-09-30 | 8,434,665 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 21,686 characters.

*The following discussion and analysis should be read in conjunction with the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and audited consolidated financial statements and related notes thereto included in our 2013 Annual Report on Form 10-K, and with the unaudited condensed consolidated financial statements and related notes thereto presented in this Quarterly Report on Form 10-Q.*

### Forward-Looking Statements

The statements contained in this report that are not historical facts are forward-looking statements that represent management’s beliefs and assumptions based on currently available information. Forward-looking statements include the information concerning our possible or assumed future results of operations, business strategies, need for financing, competitive position, potential growth opportunities, potential operating performance improvements, ability to retain and recruit personnel, the effects of competition and the effects of future legislation or regulations. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words “believes,” “intends,” “may,” “should,” “anticipates,” “expects,” “could,” “plans,” or comparable terminology or by discussions of strategy or trends. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we cannot give any assurances that these expectations will prove to be correct. Such statements by their nature involve risks and uncertainties that could significantly affect expected results, and actual future results could differ materially from those described in such forward-looking statements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

risks associated with the asphalt repair industry, including competition, increases in wages, labor relations, energy and fuel costs, actual and threatened pandemics, actual and threatened terrorist attacks, and downturns in domestic and international economic and market conditions;

risks associated with the asphalt repair industry, including changes in laws or regulations, increases in taxes, rising insurance premiums, costs of compliance with environmental laws and other governmental regulations;

the availability and terms of financing and capital and the general volatility of securities markets;

changes in the competitive environment in the asphalt repair industry;

risks related to natural disasters;

litigation; and

other risk factors discussed in the Annual Report on Form 10-K, filed by the Company with the Securities and Exchange Commission.

Should one or more of these risks materialize (or the consequences of such a development worsen), or should the underlying assumptions prove incorrect, actual results could differ materially from those expected. We disclaim any intention or obligation to update publicly or revise such statements whether as a result of new information, future events or otherwise.

### Overview and Basis of Presentation

Heatwurx, Inc. was incorporated under the laws of the State of Delaware on March 29, 2011 as Heatwurxaq, Inc. and subsequently changed its name to Heatwurx, Inc. on April 15, 2011. We have not yet commercialized our products and we are therefore classified as a development stage enterprise.

We are an asphalt preservation and repair equipment company. Our innovative, and eco-friendly hot-in-place recycling process corrects surface distresses within the top 3 inches of existing pavement by heating the surface material to a temperature between 350° and 400° Fahrenheit with our electrically powered infrared heating equipment, mechanically loosening the heated material with our processor/tiller attachment that is optimized for producing a seamless repair, and mixing in additional recycled asphalt pavement and a binder (asphalt-cement), and then compacting repaired area with a vibrating roller or compactor. We consider our equipment to be eco-friendly as the Heatwurx process reuses and rejuvenates distressed asphalt, uses recycled asphalt pavement for filler material, eliminates travel to and from asphalt batch plants, and extends the life of the roadway. We believe our equipment, technology and processes provide savings over other processes that can be more labor and equipment intensive.

In January 2014, we acquired Dr. Pave, LLC a service company offering asphalt repair and restoration utilizing the Heatwurx asphalt repair technology. The Company together with Dr. Pave offers asphalt restoration services to municipalities and the commercial sector in southern California.

Effective July 22, 2014, the Company established a new entity named Dr. Pave Worldwide LLC to house the recently announced \[on Form 8-K filed August 7, 2014\] franchise program providing franchisees with the exclusive Heatwurx equipment and processing. The franchising program is on track with submission for regulatory approval. We formally launched our franchise sales program throughout the U.S. in the third quarter of 2014.

Section 107 of the JOBS Act provides that an “emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we are choosing to “opt out” of such extended transition period, and as a result, we will comply with new or revised standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.

### Results of operations

The following discussion of the financial condition and results of operations should be read in conjunction with the financial statements included herewith. This discussion should not be construed to imply that results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future.

#### For the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013

For the nine months ended September 30, 2014, our net loss was $2,987,448, compared to a net loss of $2,261,776 for the same period of 2013. Further description of these losses is provided below.

### Revenue

Revenue decreased to approximately $186,000 for the nine months ended September 30, 2014 from approximately $242,000 for the nine months ended September 30, 2013, as a result of decreased equipment sales during the period.

### Cost of goods sold

Cost of goods sold decreased to approximately $105,000 for the nine months ended September 30, 2014 from approximately $154,000 for the nine months ended September 30, 2013.

### Selling, general and administrative

Selling, general and administrative expenses increased to approximately $2,195,000 for the nine months ended September 30, 2014 from approximately $2,067,000 for the nine months ended September 30, 2013. The increase in selling, general and administrative expenses is principally due to an increase in employee expenses of approximately $146,000; and an increase in office expenses of approximately $202,000 which includes commercial insurance, rent and other expenses incurred in the addition of Dr. Pave offices in California; offset by a decrease in advertising and promotion of approximately $117,000; and a net reduction in legal fees, offering related cost and investor relations costs of approximately $103,000.

As part of the acquisition of Dr. Pave; the Company recognized goodwill in the amount of $390,659; as part of the total consideration paid. The Company determined goodwill should be immediately impaired as of the acquisition date based on the lack of service revenue for the prior year. An impairment of goodwill from the acquisition in the amount of $390,659, was recorded as an operating expense in the income statement, during the nine months ended September 30, 2014.

### Research and Development

Research and development decreased to approximately $180,000 for the nine months ended September 30, 2014 from approximately $190,000 for the nine months ended September 30, 2013. The decrease is principally due to the termination of our research and development consulting contract with Mr. Richard Giles, fewer patent applications being filed thereby reducing the legal fees associated therewith; offset by an increase in our manufacturing research and development costs.

#### For the three months ended September 30, 2014 compared to the three months ended September 30, 2013

For the quarter ended September 30, 2014, our net loss was $791,954, compared to a net loss of $718,840 for the same period of 2013. Further description of these losses is provided below.

### Revenue

Revenue decreased to approximately $53,000 for the three months ended September 30, 2014 from approximately $126,000 for the three months ended September 30, 2013, as a result of reduced equipment sales during the period.

### Cost of goods sold

Cost of goods sold decreased to approximately $25,000 for the three months ended September 30, 2014 from approximately $80,000 for the three months ended September 30, 2013.

### Selling, general and administrative

Selling, general and administrative expenses increased to approximately $677,000 for the three months ended September 30, 2014 from approximately $664,000 for the three months ended September 30, 2013. The increase in selling, general and administrative expenses is principally due to an increase in employee expenses of approximately $44,000; an increase in office expenses of approximately $67,000 which includes commercial insurance, rent and other expenses incurred in the addition of Dr. Pave offices in California; offset by a net reduction in legal fees, offering related cost and investor relations costs of approximately $73,000; and a decrease in advertising and promotion activities related to business development of approximately $25,000.

### Research and Development

Research and development decreased to approximately $12,000 for the three months ended September 30, 2014 from approximately $55,000 for the three months ended September 30, 2013. The principal reason for the decrease is due to the termination of our research and development consulting contract with Mr. Richard Giles.

### Liquidity and capital resources

To date we have relied exclusively on private placements with a small group of investors to finance our business and operations. We have had little revenue since our inception. For the first nine months of 2014, the Company incurred a net loss of approximately $2,987,000 and utilized $2,236,000 in cash flows from operating activities. The Company had cash on hand of approximately $56,000 as of September 30, 2014. Successful completion of the Company’s development program and its transition to profitable operations is dependent upon obtaining additional financing adequate to fulfill its development and commercialization activities, and achieve a level of revenues adequate to support the Company’s cost structure. Many of the Company’s objectives to establish profitable business operations rely upon the occurrence of events outside its control; there is no assurance that the Company will be successful in accomplishing these objectives.

The Company has incurred operating losses, accumulated deficit and negative cash flows from operations since inception. As of September 30, 2014, the Company had an accumulated deficit of approximately $10,002,000.

Management anticipates that the Company will require substantial additional funds to continue operations. As of September 30, 2014, we had approximately $56,000 cash on hand and were spending approximately $275,000 per month, of which only a very small amount was satisfied by gross revenues. The amount of cash on hand is not adequate to meet our operating expenses over the next twelve months.

### Financing Activities

In October 2013, the Company initiated a follow-on non-public Series D Preferred stock offering to sell the remaining 772,352 units at $3.00 per unit for up to $2,317,056 gross proceeds. The offering includes an over-allotment of 1,000,000 units for an additional $3,000,000 in potential gross proceeds. The offering term ended May 30, 2014. During 2014, we sold 171,987 units at $3.00 per unit for gross proceeds of $515,963 and paid share issuance costs of $6,000.

The Company had an obligation to make a series of principal payments totaling $500,000 on our current senior subordinated note payable in 2014. The Company made the final required principal payments of $500,000 on the Senior Subordinated note payable during the second quarter of 2014.

In December 2013, we raised $90,000 pursuant to the terms of a Loan Agreement and the issuance of Unsecured Promissory Notes. The notes were extended to mature on June 30, 2015 and bear interest of 12% per annum, paid monthly on the first day of the month.

In January 2014, the Company assumed Secured Promissory Notes of $160,000 through the acquisition of Dr. Pave. The notes were extended to mature on June 30, 2015 and bear interest of 12% per annum, paid monthly on the first day of the month.

On January 6, 2014, we initiated a non-public debt offering of up to $1,000,000 under the terms of a Loan Agreement. Each loan is evidenced by an unsecured promissory note bearing interest at the rate of 12% per annum and maturing on January 6, 2016. Interest will be paid in equal monthly installments on the first day of each month. As additional consideration for a lender to enter into the Loan Agreement, the Company has agreed to issue to each lender one common stock purchase warrant for each $3.00 loaned to the Company, exercisable at $3.00 per share. The Warrants expire three years following the date of issuance and may not be offered for sale, sold, transferred or assigned without the consent of the Company. On February 28, 2014, we completed our $1,000,000 debt financing through the sale of notes and warrants under the Loan Agreement. The notes were in the aggregate principal amount of $850,000 and were issued with an aggregate of 283,329 warrants to the investors. We utilized $250,000 of the debt to pay our February 2014 required principal payment on the senior subordinated note payable as discussed above.

On March 1, 2014, we commenced a similar non-public offering of notes and warrants up to $3,000,000 which is intended to remain open until December 31, 2014, unless terminated sooner at the option of the Company before all of the notes are sold. The promissory notes will bear interest at 12% per annum payable monthly, with principal and unpaid interest due and payable on January 6, 2016. Persons holding promissory notes issued by the Company in prior offerings may convert these notes into the notes and warrants being offered in this new offering. Each lender in the offering will receive one warrant for each $3.00 loaned. The three-year warrants will be exercisable immediately at $3.00 per share. These securities are being offered and will be sold solely to accredited investors without selling commissions. The proceeds of this offering will be used to satisfy outstanding debt and provide working capital for the Company. As of September 30, 2014, we have received $1,299,003 under the debt offering and issued warrants to purchase 432,995 shares of our common stock.

### Cash Requirements

The issues described in the paragraphs above raise substantial doubt about the Company’s ability to continue as a going concern. Although we have a $3,000,000 non-public debt offering as noted above open through December 2014, we cannot guarantee we will be able to raise the entire offering amounts, if any. On October 1, 2014 the Company commenced a non-public equity offering of up to 3,650,807 units at $1.75 per unit, each unit consists of one common share and one-half warrant, with each whole warrant exercisable at $2.00 per share. The purchase price for the Units is payable in either cash, conversion of outstanding Series D Preferred Shares or certain outstanding promissory notes. The Company estimates $2,200,000 in potential cash proceeds from the private equity offering, after the conversion of Series D Preferred Shares and certain outstanding promissory notes. Subsequent to the quarter-end the Company raised $308,825 and issued 176,469 shares of our common stock and warrants to purchase 88,232 shares of common stock as part of the private equity offering, as of November 13, 2014. On October 9, 2014 the Company received a short- term unsecured loan in the amount of $75,000. The short-term loan bears interest at a rate of 12% per annum. The principal amount and all then-accrued interest is payable on November 15, 2014; the Company does have the option to extend the loan. We are solely reliant on raising additional capital in order to maintain our current operations. To date we have been able to raise debt and equity financing through the assistance of a small number of our investors who have been substantial participants in our debt and equity offerings since our formation. If these investors choose not to assist us with our capital raising initiatives in the future, we do not expect that we would be able to obtain any alternative forms of financing at this time and we would not be able to continue to satisfy our current or long term obligations. Based upon our current monthly spend we anticipate the need to raise at least $3,000,000 to meet our cash flow requirements for the next twelve months. The securities offered in these non-public offerings will not be and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

### Recent accounting pronouncements

The Financial Accounting Standards Board recently issued Accounting Standards Update (ASU) 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): *Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern*. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term *substantial doubt,* (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.

The Financial Accounting Standards Board recently issued ASU 2014-10, Development Stage Entities (Topic 915): *Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation*, which eliminates the financial reporting distinction of being a development stage entity within U.S. generally accepted accounting principles. Accordingly, the ASU eliminates the incremental requirements for development stage entities to (a) present inception-to-date information in the statements of income, cash flows and shareholder’s equity, (b) label the financial statements as those of a development stage entity, (c) disclose a description of the development stage activities in which the entity is engaged and (d) disclose in the first year in which the development stage entity that in prior years it had been in the development stage. The amendments related to the elimination of inception-to-date information should be applied retrospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early application of each of these amendments is permitted for any annual reporting period or interim period for which the entity’s financials statements has not yet been issued. The company has elected early application of these amendments with the quarterly report filed for September 30, 2014.

The Financial Accounting Standards Board recently issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), was issued in three parts: (a) "Summary and Amendments That Create Revenue from Contracts with Customers (Topic 606) and Other Assets and Deferred Costs—Contracts with Customers (Subtopic 340-40)," (b) "Conforming Amendments to Other Topics and Subtopics in the Codification and Status Tables," and (c) "Background Information and Basis for Conclusions." The new presentation guidance is effective for interim and annual periods beginning after December 15, 2016. We are considering the impact of the adoption of ASU 2014-09 on our results of operations, financial condition and cash flows.

## Controls and procedures

As filed, 1,221 characters.

Our principal executive officer, David Dworsky, and our principal financial and accounting officer at the time, Alexander Kramer, concluded, based on their evaluation, as of the end of the period covered by this report, that our disclosure controls and procedures (as defined in Rule 15d-15(e) under the Exchange Act) are (1) effective to ensure that material information required to be disclosed by us in reports filed or submitted by us under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and (2) designed to ensure that material information required to be disclosed by us in such reports is accumulated, organized and communicated to our management, including our principal executive officer and principal financial officer, as appropriated, to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a - 15(f)) during the three and nine months ended September 30, 2014 that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 138 characters.

See “Risk Factors” as disclosed in the Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 27, 2014.

Filed Nov 13, 2014.
Source: SEC EDGAR, the filing index for accession 0001393905-14-000606. Last ingested by Listed: Nov 14, 2026, 23:30 ET. No prices; not investment advice.
